Glucocorticoids and Cancer
- PMID: 26216001
- PMCID: PMC5546099
- DOI: 10.1007/978-1-4939-2895-8_14
Glucocorticoids and Cancer
Abstract
Unlike other steroid hormone receptors, the glucocorticoid receptor (GR) is not considered an oncogene. In breast cancer, the estrogen receptor (ER) drives cell growth, proliferation, and metastasis, and the androgen receptor (AR) plays a similar role in prostate cancer. Accordingly, treatment of these diseases has focused on blocking steroid hormone receptor function. In contrast, glucocorticoids (GCs) work through GR to arrest growth and induce apoptosis in lymphoid tissue. Glucocorticoids are amazingly effective in this role, and have been deployed as the cornerstone of lymphoid cancer treatment for decades. Unfortunately, not all patients respond to GCs and dosage is restricted by immediate and long term side effects. In this chapter we review the treatment protocols that employ glucocorticoids as a curative agent, elaborate on what is known about their mechanism of action in these cancers, and also summarize the palliative uses of glucocorticoids for other cancers.
References
-
- Kendall EC. Hormones. Annu Rev Biochem. 1941;10:285–336.
-
- Dougherty TF, White A. Effect of pituitary adrenotropic hormone on lymphoid tissue. Exp Biol Med. 1943;53(2):132–3.
-
- Heilman FR, Kendall EC. The influence of 11-dehydr0-17-hydroxycorticosterone (compound E) on the growth of a malignant tumor in the Mouse1. Endocrinology. 1944;34(6):416–20.
-
- Murphy JB, Sturm E. The effect of adrenal cortical and pituitary adrenotropic hormones on transplanted leukemia in rats. Science. 1944;99(2572):303. - PubMed
-
- Pearson OH, Eliel LP, Rawson RW, Dobriner K, Rhoads CP. Acth- and cortisone-induced regression of lymphoid tumors in man. A preliminary report. Cancer. 1949;2(6):943–5. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials